What Берлитион Treats: Main Uses and Benefits

This medication is generally used to help ease symptoms related to physical discomfort and symptoms of increased neurological activity, particularly nerve damage associated with diabetes mellitus or alcohol consumption. Treatment with Thioctic Acid is considered relevant as part of the symptomatic management of painful manifestations of diabetic sensorimotor polyneuropathy (DSPN).

It helps address symptom clusters that may become intense or disruptive, such as burning, shooting pains, tingling, and numbness. This support is typically applied across domains where additional symptomatic assistance is needed in conditions characterized by periods of heightened symptoms. This support contributes to easing the overall symptom load during periods of heightened symptoms.

“The medication may assist with managing peripheral nerve symptoms and supports general well-being in contexts of metabolic health.”

A relevant therapeutic application is also found in supportive care for the liver, easing symptoms linked to organ-specific functional stress. The medication is commonly used to help with symptomatic diabetic polyneuropathy and alcoholic polyneuropathy, and is considered relevant for managing metabolic liver stress.

Quick Fact: Supports the management of Neuropathic Burning Pain

The regulatory eligibility profile for Берлитион (Thioctic Acid) is defined by official contraindications and specific population-based restrictions detailed in government prescribing information.

Eligibility Scope

Eligibility Status	Population/Condition
Contraindicated	Known hypersensitivity to the active substance (Thioctic Acid) or any product excipients.
Recommended Use	Adults (typically 18 years and older).
Use Not Recommended	Children and adolescents (due to a lack of clinical experience).

Use during pregnancy is highly restricted and conditional, permitted only after careful consideration of the benefit/risk ratio is determined. Likewise, the medicine is not recommended while breastfeeding, as it is unknown if the active ingredient is excreted in human breast milk.

Additional caution is formally required for patients with hepatic impairment (liver function issues) due to limited clinical data in this patient group. Furthermore, patients using the medicine for diabetic nerve damage are officially advised to avoid the consumption of alcohol as it is known to impair treatment success.

Interactions with other medicines and products

Interaction Scope

Property	Value
Medicinal product categories with documented interactions	Antidiabetic Agents, Chemotherapeutic agents, Oral Metal Compounds.
Specific interacting medicines (if explicitly listed)	Cisplatin, Nateglinide.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic potentiation (additive effect on blood sugar reduction); Reduced oral absorption (decreased Thioctic Acid serum concentration due to binding to metal ions).
Timing-based interaction rules (if applicable)	Required separation of administration time for oral Thioctic Acid and oral metal compounds (e.g., iron or magnesium supplements) to avoid reduced exposure.
Population-specific interaction notes (if applicable)	Increased risk of Insulin Autoimmune Syndrome (IAS), presenting as severe hypoglycemia, in patients with specific Human Leukocyte Antigen (HLA) genotypes.
Interaction-related restrictions	Regular intake of alcohol is documented to impair the success of treatment.

---

Official Interaction Statements

• Antidiabetic Agents: Co-administration results in pharmacodynamic potentiation, increasing the potential for hypoglycemia.
• Cisplatin: The efficacy of this agent is officially documented to be reduced when Thioctic Acid is administered concurrently.
• Oral Metal Compounds: These substances decrease the oral absorption of Thioctic Acid, requiring a separation of administration time for the respective oral doses.
• Alcohol: Regular intake is officially stated to impair the success of treatment.

---

Connection to the Overall Interaction Profile

Regulatory documentation defines the interaction structure through established pharmacodynamic potentiation with glucose-lowering drugs and a reduced exposure interaction with metal-containing oral agents. This profile establishes necessary timing-based separation rules and specific restriction on substance use to prevent impairment of therapeutic outcomes, alongside noting a population-specific interaction risk related to IAS.

How Берлитион Works

Targeting Oxidative Stress and Free Radicals

This mechanism focuses on its role as a free radical scavenger of Reactive Oxygen Species (ROS), directly neutralizing harmful molecules and contributing to the regeneration of key endogenous antioxidants (like Glutathione). This foundational action protects cell components, especially those in nerve tissue, from degradation. This helps maintain the structural integrity and normal function of cells.

---

Enhancing Cellular Energy Metabolism

The drug acts as a necessary cofactor for enzymes within the mitochondria (specifically the pyruvate dehydrogenase complex), which are central to converting glucose into usable energy (ATP). By supporting this process, the mechanism enhances cellular bioenergetics and supports the overall energy supply, which is critical for the high functional demands of the nervous system.

---

Modulating Inflammatory Pathways

A third domain involves the drug's ability to modulate key intracellular signaling cascades, such as the NF-kappaB pathway. This action effectively limits the transcription and release of pro-inflammatory mediators. The resulting suppression of pro-inflammatory mediators contributes to the modulation of the cellular microenvironment and influences long-term functional stability.

How to use Берлитион (Thioctic Acid)

The official use of Thioctic Acid is structured in a biphasic approach, utilizing different administration routes depending on the required treatment phase. For the initial, intensive phase of therapy, the medicine is administered as a 600 mg dose once daily via intravenous (IV) infusion. This phase typically lasts for a course of 2 to 4 weeks.

The concentrate for the IV solution must be diluted appropriately before use and must be administered as a slow infusion over a minimum duration of 30 minutes. A critical administration constraint for the IV solution is the need to protect the solution from light throughout the preparation and infusion process.

Following the acute phase, treatment transitions to long-term oral maintenance using tablets or capsules, also at a standardized dose of 600 mg once daily. The timing for oral intake is crucial: the tablet must be consumed 30 minutes before the first meal of the day on an empty stomach with a sufficient amount of liquid. Failure to adhere to this pre-meal timing can impede absorption.

The labeled instructions specify that the medicine is not recommended for use in children and adolescents. For adult patients with concurrent diabetes, a high-level adjustment principle exists: the dosage of other anti-diabetic medications may require professional adjustment due to the potential for Thioctic Acid to reinforce blood-sugar lowering effects. A general procedural condition is the recommendation that patients abstain from consuming alcohol throughout the treatment period.

Research Evidence / Overview of Studies for Берлитион

---

Evidence for Use in Diabetic Peripheral Neuropathy

Research exploring the study drug (Alpha-Lipoic Acid) has primarily focused on adults diagnosed with diabetic sensorimotor peripheral neuropathy (DSPN)—a condition marked by functional limitations and patient-reported outcomes describing perceived discomfort. Research exploring symptom patterns often involves randomized controlled trials (RCTs), which evaluate the study drug against an inactive substance (placebo). Researchers focused on outcomes related to physical discomfort, such as pain, burning, and numbness, using specific scoring systems. Studies also monitored changes in objective measures like nerve conduction velocity.

Studies reported patterns observed in the measurements during the study period for certain symptoms. Research highlights changes measured during the study period, although the extent of these findings was observed to vary across different clinical trials. It is important to remember that these findings help contextualize how groups of patients reported their experience and research does not determine whether an individual will respond similarly.

---

Comparison of Outcomes in Research

The clinical research examined how the study drug was evaluated against a placebo in various trials. These studies explored short-term symptom changes, focusing on episodes where symptoms become more noticeable. In these comparison settings, studies reported measurements of changes in symptom score measurements, relative to the control groups. Data show patterns related to these comparisons, but the consistency of these patterns was observed to vary across the broader evidence landscape. Findings were mixed in some areas, and evidence quality varies across studies, meaning certainty remains low regarding definitive comparative advantages.

---

What is Still Uncertain About Берлитион Research

Research highlights what is known—and what is still uncertain. Data are still emerging, and there are known limitations in the existing evidence. One key limitation is that follow-up durations were limited, restricting knowledge about long-term effects. Sufficient comparative evidence is lacking in certain areas. Furthermore, existing studies provide limited insight into whether research explored whether this treatment was associated with severe, long-term complications of diabetes and neuropathy. Research is ongoing to address these gaps.

Common questions about Берлитион (FAQ)

---

Q: Which type of Berlition is better: tablets or IV drops (infusions)?

Official instructions describe a biphasic approach to treatment. An intensive phase is typically conducted using intravenous (IV) infusion, which is followed by a long-term maintenance phase using oral tablets. Therefore, the different forms serve sequential phases of the overall treatment plan.

---

Q: How long does one usually need to take Berlition on the standard scheme?

According to official product information, the initial intensive intravenous phase typically lasts 2 to 4 weeks. Following this, the treatment transitions to a long-term oral maintenance therapy. The overall duration of the treatment is determined by a medical professional based on the specific condition.

---

Q: Can Berlition be combined with other pain relief medications?

The official interaction statements focus on antidiabetic agents, cisplatin, and oral metal compounds. Other general pain relief medications are not typically cited as requiring restriction in the product’s regulatory documents.

---

Q: What is the difference between taking Berlition before a meal and after a meal?

Official instructions state that the oral tablet must be taken 30 minutes before the first meal on an empty stomach. This timing is specified because food intake at the time of administration can impede the absorption of the active substance, Thioctic Acid.

---

Q: Can Berlition be used for prevention?

The official therapeutic indications for this medicine, as documented in regulatory sources, are for the treatment of defined conditions, such as diabetic peripheral neuropathy. Regulatory documents do not state or support its use for general prevention or prophylaxis.

---

Q: How soon after starting the treatment can one feel any effect?

Studies and official information indicate that the onset of symptom changes is generally described as gradual. Clinical trials exploring symptom patterns typically involve an intensive treatment phase lasting 2 to 4 weeks before initial effects are measured.

---

Q: What should I do if I missed a Berlition tablet dose?

Official product information states that if a dose of the tablet is missed, the patient should not take a double dose to make up for the omission. The next scheduled dose should be taken at the usual time.

---

Q: Is a doctor's prescription needed to buy Berlition?

Yes, this medicine is formally classified and authorized by regulatory bodies as a prescription-only medicinal product.

---

Q: Is Berlition a homeopathy or a medicinal product?

Official regulatory documents classify this medicine as a prescription-only medicinal product and a pharmaceutical preparation. It contains the active substance Thioctic Acid, which is a synthetic version of a naturally occurring vitamin-like compound.

---

Q: Can I drive a car while undergoing treatment with Berlition?

Official safety information describes potential side effects that may affect driving ability. These include common effects like dizziness and the rare possibility of symptoms related to hypoglycemia (low blood sugar). Patients should be aware of these potential effects on their ability to drive or operate machinery.

---

Q: What are the signs that Berlition is not suitable for a patient?

Official safety information lists formal contraindications (e.g., known hypersensitivity to the active substance) which would make the medicine unsuitable. Additionally, a patient may experience documented adverse reactions, including rare severe allergic events, which indicate poor tolerance.

---

Q: Can Berlition cause drowsiness or insomnia?

Adverse reactions documented that affect the nervous system commonly include headache and dizziness. While drowsiness or insomnia are not typically listed among the most common effects, they are potential nervous system effects documented in the broader clinical use reports.

---

Q: Why does the leaflet mention galactose intolerance?

The tablet form of the medicine contains an excipient, such as lactose, derived from milk sugar. Official instructions include a warning to inform patients with rare hereditary problems of galactose intolerance or related sugar malabsorption issues.

---

Q: Is there research on using Berlition for hearing problems?

Research evidence summaries primarily focus on the medicine's use for treating symptoms of diabetic sensorimotor peripheral neuropathy. Studies on its application for hearing problems are not highlighted in the primary regulatory evidence landscape.

---

Q: What can enhance or weaken the effect of Berlition?

Official interaction statements describe how oral metal compounds, such as iron or magnesium supplements, can reduce the oral absorption of the medicine. Furthermore, the regular intake of alcohol is formally documented to impair the success of treatment.

---

Q: Is it true that Berlition helps with chronic fatigue syndrome?

The official therapeutic indications for this medicine, as documented in regulatory sources, are for the treatment of defined conditions, such as diabetic peripheral neuropathy. Regulatory documents do not state or support its use for chronic fatigue syndrome.

---

Q: What do I need to know about storing the Berlition infusion solution?

Official storage information states that the concentrate should be kept in the original carton to protect it from light, and it should not be frozen or refrigerated. The diluted infusion solution must also be protected from light and used within approximately 6 hours of its preparation.

How to Store and Dispose of Berlithion (Alpha-Lipoic Acid)

Official regulatory information outlines specific requirements for storing, handling, and disposing of this medicine to maintain its stability.

Storage Requirement	Conditions
Temperature	Store concentrate below 25 C. Store hard capsules below 30 C. Do not freeze or refrigerate the concentrate.
Light Protection	Must be kept in the original outer carton to protect from light. The diluted infusion solution must also be protected from light during administration.
Post-Dilution Stability	The diluted infusion solution is stable for approximately 6 hours when protected from light and must be used within this time.
Child Safety	Keep this medicine out of the sight and reach of children.

Any unused medicine or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of this medicine via household waste or wastewater, as this helps to protect the environment.